AccScience Publishing / JCTR / Volume 5 / Issue 3 / DOI: 10.18053/jctres.05.202003.006
ORIGINAL ARTICLE

Cardiovascular, endothelial function, and immune markers in response to  treatment with a polysaccharide in HIV+  adults in a randomized, doubleblind placebo-controlled trial

John E. Lewis1* Steven E. Atlas1 Muhammad H. Abbas1 Ammar Rasul1 Ashar Farooqi1 Laura A. Lantigua1 Frederick Michaud1 Sharon Goldberg2 Lucas C. Lages1 Jinrun Gao3 Oscar L. Higuera1 Andrea Fiallo1 Philip D. Harvey1 Eduard Tiozzo1 Judi M. Woolger4 Stephanie Ciraula4 Armando Mendez4 Allan Rodriguez4 Janet Konefal5
Show Less
1 Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL, USA
2 Department of Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA
3 Barclay’s, Inc., Wilmington, DE, USA
4 Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
5 Department of Family Medicine and Community Health, University of Miami Miller School of Medicine, Miami, FL, USA
Submitted: 23 May 2019 | Revised: 26 November 2019 | Accepted: 13 December 2019 | Published: 13 April 2020
© 2020 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Background and Aim: Given the ongoing problems of hypertension and endothelial dysfunction in the HIV population, the primary objective of the study was to assess cardiovascular, endothelial function, and immune markers in response to Rice Bran Arabinoxylan Compound (RBAC) treatment in a sample of HIV+ adults on antiretroviral therapy (ART).
Study design: A randomized double-blind placebo-controlled trial of six months was used to execute the study.
Methods: Forty-seven subjects were enrolled and randomly assigned to one of two study conditions (n = 22 RBAC and n = 25 placebo) for six months with assessments at baseline and three and six months. A multivariate repeated measures analysis of variance model was used to assess the differences between RBAC and placebo groups in cardiovascular (systolic blood pressure), endothelial function (skin blood flow in response to nitric oxide), and immune (CD4+ cell count) markers from baseline to six months.
Results: The effect of treatment (RBAC versus placebo) was significant (Wilks’ λ = 0.92, F[3, 102] = 3.07, p = 0.03). The effect of time was significant (Wilks’ λ = 0.10, F[2, 103] = 474.6, p < 0.001). The overall interaction between treatment and time was significant (Wilks’ λ = 0.92, F[2, 103] = 4.58, p = 0.01). Time contrasts showed that a difference in the overall dependent variable did not occur from baseline to 3 months (F[1, 104] = 2.7, p = 0.10), marginally occurred from baseline to 6 months (F[1, 104] = 3.2, p = 0.08), and was significant from 3 to 6 months (F[1, 104] = 6.43, p = 0.01).
Conclusions: The overall significant interaction suggests varying responses in the dependent variables between RBAC and placebo over time, which is being driven by systolic blood pressure, as it decreased in the RBAC group, but increased in the placebo group. Additionally, CD4+ manifested a non-significant increase from baseline to 3 months then decreased from 3 to 6 months in the RBAC group, whereas it decreased at 3 months followed by a slight increase at 6 months in the placebo group. Skin blood flow in response to nitric oxide improved non-significantly overall in both groups, but worsened from 3 to 6 months in the placebo group. Thus, RBAC treatment may contribute to modest short-term improvements in systolic blood pressure, endothelial function, and CD4+ cell count, which could help improve the overall health profile of HIV+ adults.
Relevance for patients: Persons with HIV on ART suffer disproportionately from hypertension and endothelial dysfunction compared to the non-infected population, and conventional medical therapy does not alleviate these issues. RBAC is a safe, low-risk alternative that may help to improve the overall quality of life of these patients through modest improvements in these biomarkers plus CD4+ cell count.

Keywords
CD4+
endothelial function
HIV
hypertension
nutritional supplement
polysaccharide
rice bran arabinoxylan compound
systolic blood pressure
Conflict of interest
The authors declare they have no competing interests.
References

[1] Centers for Disease Control and Prevention. HIV Prevalence Estimates--United States, 2006. MMWR Morb Mortal WklyRep 2008;57:1073-6.

[2] Centers for Disease Control and Prevention. HIV Surveillance Report. Atlanta, Georgia, United States: Centers for Disease Control and Prevention; 2015.

[3] Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, FratinoP, Sacchi P, et al. Hypertension among HIV Patients: Prevalence and Relationships to Insulin Resistance and Metabolic Syndrome. J Hypertens 2003;21:1377-82.

[4] Peck RN, Shedafa R, Kalluvya S, Downs JA, Todd J, Suthanthiran M, et al. Hypertension, Kidney Disease, HIV and Antiretroviral Therapy among Tanzanian Adults: ACross-sectional Study. BMC Med 2014;12:125.

[5] Xu Y, Chen X, Wang K. Global Prevalence of Hypertension among People Living with HIV: A Systematic Review and Meta-analysis. JAm Soc Hypertens 2017;11:530-40.

[6] Sinha A, Ma Y, Scherzer R, Hur S, Li D, Ganz P, et al. Role of t-cell Dysfunction, Inflammation, and Coagulation in Microvascular Disease in HIV. JAm Heart Assoc 2016;5

[7] IantornoM, ScharM, Soleimanifard S, Brown TT, MooreR, Barditch-Crovo P, et al. Coronary Artery Endothelial Dysfunction is Present in HIV-Positive Individuals without Significant Coronary Artery Disease. AIDS 2017;31:1281-9.

[8] Hove-Skovsgaard M, Gaardbo JC, Kolte L, Winding K, Seljeflot I, Svardal A, et al. HIV-Infected Persons with Type 2 Diabetes Show Evidence of Endothelial Dysfunction and Increased Inflammation. BMC Infect Dis 2017;17:234.

[9] Nuesch R, Wang Q, Elzi L, Bernasconi E, Weber R, Cavassini M, et al. Risk of Cardiovascular Events and Blood Pressure Control in Hypertensive HIV-Infected Patients: Swiss HIV Cohort Study (SHCS). J Acquir Immune Defic Syndr 2013;62:396-404.

[10] Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease. J Clin Endocrinol Metab 2007;92:2506-12.

[11] Phillips AN, Carr A,Neuhaus J, VisnegarwalaF, Prineas R, Burman WJ, et al. Interruption of Antiretroviral Therapy and Risk of Cardiovascular Disease in Persons with HIV-1 Infection: Exploratory Analyses from the Smart Trial. Antivir Ther 2008;13:177-87.

[12] Armah KA, Chang CC, Baker JV, Ramachandran VS, Budoff MJ, Crane HM, et al. Prehypertension, Hypertension, and the Risk of Acute Myocardial Infarction in HIV-Infected and-Uninfected Veterans. Clin Infect Dis 2014;58:121-9.

[13] Bloomfield GS, Hogan JW, KeterA, Holland TL, Sang E, Kimaiyo S, et al. Blood Pressure Level Impacts Risk of Death Among HIV Seropositive Adults in Kenya: A Retrospective Analysis of Electronic Health Records. BMC Infect Dis 2014;14:284.

[14] Fahme SA, Bloomfield GS, Peck R. Hypertension in HIV- Infected Adults: Novel Pathophysiologic Mechanisms. Hypertension 2018;72:44-55.

[15] Mai J, Virtue A, Shen J, Wang H, Yang XF. An Evolving New Paradigm: Endothelial Cells--Conditional Innate Immune Cells. J Hematol Oncol 2013;6:61.

[16] Choi J, Enis DR, Koh KP, Shiao SL, Pober JS. T Lymphocyte-endothelial Cell Interactions. Annu Rev Immunol 2004;22:683-709.

[17] Auclair M, Afonso P, CapelE, Caron-Debarle M, Capeau J. Impact of Darunavir, Atazanavirand Lopinavir Boosted with Ritonavir on Cultured Human Endothelial Cells: Beneficial Effect of Pravastatin. AntivirTher 2014;19:773-82.

[18] Kalebic T, Kinter A, Poli G, Anderson ME, Meister A, FauciAS. Suppression of Human Immunodeficiency Virus Expression in Chronically Infected Monocytic Cells by Glutathione, Glutathione Ester, and n-acetylcysteine. Proc Natl Acad Sci U SA 1991;88:986-90.

[19] IvanovAV,Valuev-EllistonVT, Ivanova ON, Kochetkov SN, Starodubova ES, Bartosch B, et al. Oxidative Stress during HIV Infection: Mechanisms and Consequences. Oxid Med Cell Longev 2016;2016:8910396.

[20] Ghoneum M, Matsuura M. Augmentation of Macrophage Phagocytosis by Modified Arabinoxylan Rice Bran (mgn-3/ biobran). Int J ImmunopatholPharmacol 2004;17:283-92.

[21] Tazawa K, Namikawa H, Oida N, Masada M, Maeda H. Scavenging Activity of Modified Arabinoxylane from Rice Bran (biobran/mgn-3) with Natural Killer Cell Activity on Free Radicals. Biotherapy 2000;14:493-5.

[22] Ali K, Melillo A, Leonard S, Asthana D, Woolger J, Wolfson A, et al. An Open-label, Randomized Clinical Trial to Assess the Immunomodulatory Activity of a Novel Oligosaccharide Compound in Healthy Adults. Funct Foods Health Dis 2012;2:265-79.

[23] Lewis JE, Atlas SE, Higuera OL, Fiallo A, Rasul A, FarooqiA, et al. The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in adults with Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med 2018;2018:1751583.

[24] Lewis JE, Atlas SE, Abbas MH, Rasul A, Farooqi A, Lantigua LA, et al. The Novel Effects of a Hydrolyzed Polysaccharide Dietary Supplement on Immune, Hepatic, and Renal Function in Adults with HIV in a Randomized, Double-blind Placebo-control Trial. J Diet Suppl 2018:1-13.

[25] Nanzigu S, Kiguba R, Kabanda J, Mukonzo JK, Waako P, Kityo C, et al. Poor Immunological Recovery among Severely Immunosuppressed Antiretroviral Therapy-Naive Ugandans. HIV AIDS (Auckl) 2013;5:309-19.

[26] Merci NM, Emerence U, Augustin N, Habtu M, Julie I, Angelique T, et al. CD4+ Cells Recovery in HIV Positive Patients with Severe Immunosuppression at Haart Initiation at Centre Medico-Social Cor-Unum, Kigali. Pan Afr Med J 2017;26:14.

[27] Zhu J, Yamane H, Paul WE. Differentiation of Effector CD4 t Cell Populations (*). Annu Rev Immunol 2010;28:445-89.

[28] Twizerimana AP, Mwatha J, Musabyimana JP, Kayigi E, Jde DH, Karanja SM, et al. Immunological Profiles in HIV Positive Patients Following Haart Initiation in Kigali, Rwanda. East Afr Med J 2014;91:261-6.

[29] Manner IW, Troseid M, Oektedalen O, Baekken M, Os I. Low Nadir CD4 Cell Count Predicts Sustained Hypertension in HIV-Infected Individuals. J Clin Hypertens (Greenwich) 2013;15:101-6.

[30] Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral Medications Associated with Elevated Blood Pressure among Patients Receiving Highly Active Antiretroviral Therapy. AIDS 2006;20:1019-26.

[31] Lewis JE, Atlas SE, Rasul A, Farooqi A, Lantigua L, Higuera OL, et al. New Method of Sudomotor Function Measurement to Detect Microvascular Disease and Sweat Gland Nerve or Unmyelinated c Fiber Dysfunction in Adults with Retinopathy. J Diabetes Metab Disord 2017;16:26.

[32] Lewis JE, Lantigua L, Atlas SE, Lopez J, Mendez A, Goldberg S, et al. A Cross-sectional Assessment to Detect Type 2 Diabetes with Endothelial and Autonomic Nervous System Markers Using a Novel System. J Diabetes Metab Disord 2014;13:118.

[33] Lewis JE, Tannenbaum SL, Gao J, Melillo AB, Long EG, Alonso Y, et al. Comparing the Accuracy of ES-BC,EIS GS, and ES Oxi on Body Composition, Autonomic Nervous System Activity, and Cardiac Output to Standardized Assessments. Med Devices (Auckl) 2011;4:169-177.

[34] Gandhi P, Rao, G. Detection of Neuropathy Using a Sudomotor Test in Type 2 Diabetes. Degener Neurol Neuromuscul Dis 2015;5:1-7.

[35] De Souza AL, Batista GA, Alegre SM. Assessment of Insulin Sensitivity by the Hyperinsulinemic Euglycemic Clamp: Comparison with the Spectral Analysis of Photoplethysmography. J Diabetes Complications 2017;31:128-33.

[36] MaffongelliG, AlteriC, GentilottiE, BertoliA, RicciardiA, Malagnino V, et al. Impact of HIV-1 Tropism on the Emergence of Non-aids Events in HIV-infected Patients Receiving Fully Suppressive Antiretroviral Therapy. AIDS 2016;30:731-41.

[37] Freiberg MS, Chang CC, Kuller LH, Skanderson M, LowyE, Kraemer KL, et al. HIV Infection and the Risk of Acute Myocardial Infarction. JAMA Intern Med 2013;173:614-22.

[38] Hsue PY, Deeks SG, Hunt PW. Immunologic Basis of Cardiovascular Disease in HIV-Infected Adults. J Infect Dis 2012;205 Suppl 3:S375-82.

[39] Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El- Sadr W, et al. Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected with Human Immunodeficiency Virus: The Data Collection on Adverse Events of Anti-HIV Drugs (d: A:D study). Circulation 2009;119:805-11.

[40] Chow D, Kocher M, Shikuma C, Parikh N, Grandinetti A, Nakamoto B, et al. Effects of Antiretroviral Therapy on Autonomic Function in Early HIV Infection: A Preliminary Report. Int J Med Sci 2012;9:397-405.

[41] Grigoletti SS, Guindani G, Moraes RS, Ribeiro JP, Sprinz E. Short-term Folinic Acid Supplementation Improves Vascular Reactivity in HIV-Infected Individuals: A Randomized Trial. Nutrition 2013;29:886-91.

[42] Grigoletti SS, Ribeiro JP, Sprinz E, Ribeiro PA. Short- Term Folinic Acid Supplementation and Aerobic Exercise Improve Vascular Reactivity in HIV-Infected Individuals. HIV Clin Trials 2018;19:148-51.

[43] Teixeira A, Luzia LA, de Souza SJ, de Almeida Petrilli A, Pontilho PM, de Souza JM, et al. The Impact of Dark Chocolate Intake on Arterial Elasticity in Individuals with HIV/AIDS Undergoing Art: A Randomized, Double-blind, Crossover Trial. Food Funct 2017;8:2212-9.

[44] Merchant AT, Msamanga G, Villamor E, Saathoff E, O’Brien M, Hertzmark E, et al. Multivitamin Supplementation of HIV-positive Women during Pregnancy Reduces Hypertension. JNutr 2005;135:1776-81.

[45] Kaiser JD, Campa AM, Ondercin JP, Leoung GS, Pless RF, Baum MK. Micronutrient Supplementation Increases CD4 Count in HIV-infected Individuals on Highly Active Antiretroviral Therapy: A Prospective, Double-blinded, Placebo-controlled Trial. J Acquir Immune Defic Syndr 2006;42:523-8.

Share
Back to top
Journal of Clinical and Translational Research, Electronic ISSN: 2424-810X Print ISSN: 2382-6533, Published by AccScience Publishing